News

»News
News 2017-09-18T14:37:31+00:00
Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors
– Company Advancing Multiple Programs in Orphan Disease Pipeline

PALO ALTO, Calif., September 18, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Evan Loh, MD to its Board of Directors.  Dr. Loh’s clinical development and regulatory experience spans nearly two decades across all phases of development ranging from discovery to registration, across multiple therapeutic areas including oncology, infectious diseases, inflammation and rare diseases.  The company concurrently announced that Ed Engleman, MD, Managing Partner at Vivo Capital and a founding venture investor, is departing from the Board.

“We are very pleased to have Dr. Loh join our Board of Directors and believe his experience will be invaluable to our company,” stated Thomas Dietz, PhD, Chairman of the Board of Eiger.  “Evan has a proven track record in the pharmaceutical industry and brings relevant clinical, regulatory, and operational experience, having served in broad executive management roles at both large pharma and start up biotechnology companies.  We believe his broad operational background, including financing, will be invaluable as we plan for late stage development of the Eiger pipeline.  We look forward to Evan’s strategic insights and contributions to the Board.”

“I am very pleased to be elected to Eiger’s Board at this exciting point in the Company’s development, and look forward to working closely with the other Board members and Eiger’s management team to advance a diverse set of exciting clinical stage orphan disease programs in therapeutic areas of high unmet medical need,” said Dr. Loh.

“We also wish to thank Ed Engleman for his many contributions to Eiger during his near decade-long tenure on our Board.  Dr. Engleman’s involvement as an investor, clinician, and Stanford faculty member has contributed significantly to the Company’s evolution to an exciting public biopharmaceutical company,” commented Dr. Dietz.  “It’s been a privilege to have been with Eiger from the very beginning and to work alongside an extraordinary management team and Board.  Evan Loh will be an excellent addition to the Board to move the company forward,” stated Dr. Engleman.

Evan Loh, MD, is President, Chief Operating Officer and Chief Medical Officer, as well as a member of the Board of Directors at Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK).  Prior to Paratek’s merger with Transcept Pharmaceuticals, Dr. Loh served as Paratek’s Executive Chairman of the Board of Directors from June 2012 to June 2014.  Previously, Dr. Loh served as Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, at Pfizer.  While at Pfizer, Dr. Loh’s responsibilities included scientific, operational, and strategic drug development oversight for all pre-proof of concept development phase programs and leading portfolio prioritization.  Dr. Loh joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President, Multiple Therapeutic Areas, where he was responsible for global development strategy and clinical operational deliverables, including leading the successful global registration programs for Torisel® and Tygacil®.

Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania, School of Medicine.  Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School.  He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women’s Hospital in Boston, MA.

About Eiger
Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases.  The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is identified, and for which an effective therapy is urgently needed.  For more information, please visit the Company’s website at www.eigerbio.com.

Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties.  All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives, intentions, beliefs and expectations of management are forward-looking statements.  These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning.  Examples of such statements include, but are not limited to, whether or not pegylated interferon lambda-1a, lonafarnib, ubenimex or exendin 9-39, including SC formulations, may be further developed and approved, whether additional studies of exendin 9-39 will show safety and activity consistent with early clinical results, including the interim results of the MAD study, or that the new liquid formulation will be consistent with results seen with IV and SC formulations of exendin 9-39, statements relating to the availability of cash for Eiger’s future operations, Eiger’s ability to develop its drug candidates for potential commercialization, the timing of the commencement and number and completion of Phase 2 trials and whether the products can be successfully developed or commercialized.  Various important factors could cause actual results or events to differ materially from the forward-looking statements that Eiger makes, including the risks described in the “Risk Factors” sections in the Quarterly Report on Form 10-Q for the three months ended June 30, 2017 and our periodic reports filed with the Securities and Exchange Commission.  Eiger assumes no obligation to update any forward-looking statements, except as required by law.

Eiger BioPharmaceuticals

SOURCE Eiger BioPharmaceuticals, Inc.
Investors: Ingrid Choong, PhD Email: ichoong@eigerbio.com Phone: 1-650-619-6115

PDF Icon

Date Title (click to view the full PR) PDF
September 18, 2017 Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors PDF Icon
September 5, 2017 Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PDF Icon
August 30, 2017 Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences PDF Icon
August 14, 2017 Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results PDF Icon
August 8, 2017 Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th PDF Icon
July 27, 2017 Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PDF Icon
July 24, 2017 Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PDF Icon
June 14, 2017 Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals PDF Icon
June 14, 2017 Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors PDF Icon
June 12, 2017 Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego PDF Icon
June 6, 2017 Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients PDF Icon
May 30, 2017 Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th PDF Icon
May 17, 2017 Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema PDF Icon
May 15, 2017 Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension PDF Icon
May 12, 2017 Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results PDF Icon
May 8, 2017 Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago PDF Icon
May 4, 2017 Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City – Phase 2 LIBERTY Study Update for Ubenimex in PAH PDF Icon
May 3, 2017 Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection – LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling PDF Icon
April 24, 2017 Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago PDF Icon
April 21, 2017 Eiger Announces Additional Phase 2 Clinical Trial Results for Lonafarnib at The International Liver Congress™ 2017 PDF Icon
April 18, 2017 Eiger Announces Industry Veteran Lisa Porter, MD to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia – Novel Liquid Formulation of Exendin 9-39 Advancing PDF Icon
April 6, 2017 Eiger Announces Abstracts and Presentations of LOWR HDV Program at the European Association for the Study of the Liver (EASL) Meeting PDF Icon
March 23, 2017 Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results PDF Icon
January 31, 2017 Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th PDF Icon
January 3, 2017 Eiger Completes $25 Million Debt Financing with Oxford Finance PDF Icon
January 3, 2017 Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)— First-in-class inhibitor of LTB4 targeting disease modification in PAH PDF Icon
Date Title (click to view the full PR) PDF
December 12, 2016 Eiger Announces Multiple Advances in Exendin 9-39 Program for the Treatment of Post-Bariatric Hypoglycemia (PBH) – Positive Interim Data from Phase 2 Multiple-Ascending Dose Study – Novel Liquid Formulation of Exendin 9-39 – US Orphan Designation for Hyperinsulinemic Hypoglycemia PDF Icon
November 29, 2016 Eiger Updates Progress in Clinical Development Program for Exendin 9-39 to Treat Post-Bariatric Hypoglycemia (PBH) – Exendin 9-39 investigational new drug (IND) application filed – PBH Analyst / Key Opinion Leader Event planned December 9th – Multiple-ascending dose (MAD) study interim data to be presented PDF Icon
November 14, 2016 Eiger Announces Additional LOWR HDV Program Data, Clinical and Regulatory Plans at the American Association for the Study of Liver Diseases (AASLD) Meeting – Update on Data Presented and Analyst Meeting through Monday Evening PDF Icon
November 14, 2016 Eiger Announces Positive Phase 2 Data at the American Association for the Study of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified with Lonafarnib Therapy in LOWR HDV Program – Data Presented through Monday Morning PDF Icon
November 8, 2016 Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results PDF Icon
October 24, 2016 Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign to Expand Awareness and Testing for HDV Infection – Collaboration with ARUP Laboratories and Hepatitis B Foundation – HDV viral load assay now available in U.S. PDF Icon
October 19, 2016 Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection – LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PDF Icon
October 17, 2016 Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA) PDF Icon
October 13, 2016 Eiger Announces Abstracts and Presentations of LOWR HDV Program at the American Association for the Study of Liver Diseases (AASLD) Meeting PDF Icon
September 7, 2016 Eiger Announces Completion of Dosing in Phase 2 LOWR HDV – 4 Study at Hannover Medical School PDF Icon
September 6, 2016 Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th PDF Icon
September 1, 2016 Eiger BioPharmaceuticals to Present at the 5th Annual Liolios Gateway Conference on September 7, 2016 PDF Icon
August 18, 2016 Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock PDF Icon
August 17, 2016 Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PDF Icon
August 10, 2016 Eiger BioPharmaceuticals Reports Second Quarter 2016 Financial Results PDF Icon
July 28, 2016 Eiger BioPharmaceuticals Announces Partnership with the Hepatitis B Foundation – Raising Awareness of Hepatitis Delta Virus Co-Infection PDF Icon
July 25, 2016 Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema PDF Icon
July 20, 2016 Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV – 3 Study at National Institutes of Health (NIH) PDF Icon
July 18, 2016 Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension PDF Icon
July 6, 2016 Eiger BioPharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12th PDF Icon
June 13, 2016 Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia PDF Icon
June 6, 2016 Eiger to Participate in Jefferies 2016 Healthcare Conference PDF Icon
May 10, 2016 Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery PDF Icon
May 3, 2016 Eiger Bio Strengthens Senior Management Team with Announcement of Debra Odink, PhD as Senior Vice President of Technical Operations PDF Icon
April 20, 2016 Eiger BioPharmaceuticals Announces License of Worldwide Rights to Pegylated Interferon Lambda-1a from Bristol-Myers Squibb PDF Icon
April 4, 2016 Eiger BioPharmaceuticals Strengthens Board of Directors with Addition of Industry Veteran Charles J. “Chuck” Bramlage PDF Icon
March 30, 2016 Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Meeting PDF Icon
March 28, 2016 Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency PDF Icon
March 22, 2016 Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol (NASD: EIGR, as of March 23) Developing a Clinical Stage Pipeline of Orphan Disease Programs PDF Icon
March 22, 2016 Celladon Announces Results of Special Meeting PDF Icon
March 14, 2016 Eiger Announces Completion of Enrollment of Phase 2 LOWR HDV – 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 4) Study at Hannover Medical School PDF Icon
March 9, 2016 ISS and Glass Lewis Recommend Celladon Corporation Shareholders Vote “FOR” Proposed Merger PDF Icon
February 29, 2016 Eiger to Participate in Cowen & Company 2016 Health Care Conference PDF Icon
February 11, 2016 Celladon Sets Date for Special Meeting of Stockholders PDF Icon
January 19, 2016 Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV – 3 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 3) Study at National Institutes of Health (NIH) PDF Icon
January 6, 2016 Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LOWR HDV – 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus – 4) Study at Hannover Medical School in Hannover, Germany PDF Icon
Date Title (click to view the full PR) PDF
December 15, 2015 Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering Bestatin™ (Ubenimex) for the Treatment of Pulmonary Arterial Hypertension PDF Icon
November 30, 2015 Eiger BioPharmaceuticals Granted Orphan Drug Status for Ubenimex in Pulmonary Arterial Hypertension PDF Icon
November 18, 2015 Eiger BioPharmaceuticals and Celladon Corporation Sign Merger Agreement PDF Icon
November 12, 2015 Eiger BioPharmaceuticals Announces Acquisition of Exclusive License to Program for Treatment of Post-Bariatric Hypoglycemia from Stanford University – Clinical Proof of Concept Data Already Generated in Patients PDF Icon
November 11, 2015 Eiger BioPharmaceuticals Announces Acquisition of Exclusive License to Lymphedema Program from Stanford University – Novel Target Identified as Potential Therapeutic Approach for Lymphedema PDF Icon
November 10, 2015 Eiger BioPharmaceuticals Announces Acquisition of Exclusive License to Pulmonary Arterial Hypertension (PAH) Program from Stanford University PDF Icon
November 9, 2015 Eiger BioPharmaceuticals Announces License Agreement with Nippon Kayaku to Develop Bestatin™ (ubenimex) for Inflammatory Diseases Involving LTB4 – First Clinical Target – Pulmonary Arterial Hypertension (PAH) PDF Icon
October 23, 2015 Eiger BioPharmaceuticals Appoints Thomas J. Dietz, Ph.D. to the Eiger Board of Directors PDF Icon
October 20, 2015 Eiger BioPharmaceuticals Appoints Eduardo Martins, M.D., D.Phil., as Senior Vice President, Liver and Infectious Diseases Drug Development PDF Icon
August 17, 2015 Eiger BioPharmaceuticals Announces Key Operational Hires to Senior Management Team: Jim Welch, Chief Financial Officer & Jim Shaffer, Chief Business Officer PDF Icon
July 20, 2015 The Lancet Infectious Diseases Journal Publishes Results of Phase 2 Study of Lonafarnib in Hepatitis Delta Virus (HDV) Infected Patients PDF Icon
April 28, 2015 Eiger BioPharmaceuticals Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) PDF Icon
April 20, 2015 FDA Grants Fast Track Designation to Eiger Bio’s Lonafarnib for Hepatitis Delta Virus (HDV) Infection PDF Icon
April 14, 2015 Eiger BioPharmaceuticals Announces Senior Staff Appointments in Clinical Development and Regulatory Affairs: Dr. Joanne Quan, M.D., as Chief Medical Officer & Dr. Shelly Xiong, Ph.D., as Vice President of Regulatory Affairs PDF Icon
April 13, 2015 Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta (HDV) at the European Association for the Study of the Liver Conference – April 22 to 26, 2015 PDF Icon
February 23, 2015 Eiger BioPharmaceuticals Announces Presentation of Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib – NIH Principal Investigator to Present Abstract and Poster at Conference on Retroviruses and Opportunistic Infections (CROI) PDF Icon